Drug Trial Radar · NCT01011621
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Last checked: Nov 19, 2026Latest source record: Nov 11, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
170
Planned (sponsor's estimate)
Start
Feb 2010
Primary completion
Feb 2012
Sponsor
- Lead sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids require formulations with mild to moderate potency while high-potency corticosteroids era required in less responsive conditions. The aim of the present study is to compare the safety and efficacy of prednisolone acetate 0.5% cream (mild-potency non-fluoridated corticosteroid) versus betamethasone valerate 0.1% cream (high-potency fluoridated corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis is that 0.5% prednisolone cream will be as effective as 0.1% betamethasone cream and will be an alternative option to treat corticosensitive dermatosis in body areas where the use of fluoridated corticosteroids is contraindicated, such as the face.
Conditions
- Dermatitis, Atopic
- Dermatitis, Contact
- Dermatitis, Seborrheic
- Psoriasis
Interventions
0.5% prednisolone acetate creamDrug
Small amount applied over the lesion twice a day for 14 days.
0.1% betamethasone valerate creamDrug
Small amount applied over the lesion twice a day for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate efficacy and safety of 0.5% prednisolone cream in comparison to 0.1% betamethasone cream in the treatment of corticosensitive dermatosis.Time frame: 14 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.